Adjuvant ET represents the standard of care in hormone receptor-positive BC patients, which represent about 75–80% of all BC diagnoses, as it was shown to significantly reduce the risk of recurrence and cancer-related death. This evidence concerns the gene NR4A1 and breast cancer.